Literature DB >> 8787702

Ciba Corning ACS:180 testosterone assay evaluated.

M J Wheeler1, A D'Souza, J Matadeen, P Croos.   

Abstract

A fully automated direct assay of testosterone has been developed for the Ciba Corning ACS:180 immunoassay system. We have evaluated this method and compared specimen results with those from the Diagnostic Products Corp. (DPC) and Medgenix direct assays and an in-house extraction assay. Accuracy of the method was assessed by measuring GC-MS-targeted serum pools. Within-assay im- precision was <6% and between-assay imprecision <9% over the concentration range examined. High concentrations of lipid caused an increase in the measured testosterone but other potential interferents were without effect. Recovery was quantitative but was affected by sex-hormone-binding globulin. The method was positively biased with respect to the DPC and Medgenix assays but negatively biased with the extraction assay. Measurement of the GC-MS-targeted serum pools showed the assay to overestimate recovery by approximately 13%. The ACS:180 assay is particularly attractive as a routine assay because it is fully automated, obtains the first result in only 15 min, and shows good assay performance.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8787702

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  9 in total

1.  Bone mineral density and osteoporosis among a predominantly Caucasian elderly population in the city of São Paulo, Brazil.

Authors:  Marilia Brasilio Rodrigues Camargo; Maysa Seabra Cendoroglo; Luiz Roberto Ramos; Maria do Rosario Dias de Oliveira Latorre; Gabriela Luporini Saraiva; Andrea Lage; Nelson Carvalhaes Neto; Lara Miguel Quirino Araújo; José Gilberto H Vieira; Marise Lazaretti-Castro
Journal:  Osteoporos Int       Date:  2005-02-12       Impact factor: 4.507

Review 2.  Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer.

Authors:  Laurence Klotz; Rodney H Breau; Loretta L Collins; Martin E Gleave; Tom Pickles; Frederic Pouliot; Fred Saad
Journal:  Can Urol Assoc J       Date:  2017 Jan-Feb       Impact factor: 1.862

3.  Testosterone suppression in the treatment of recurrent or metastatic prostate cancer - A Canadian consensus statement.

Authors:  Laurence Klotz; Bobby Shayegan; Chantal Guillemette; Loretta L Collins; Geoffrey Gotto; Dominique Guérette; Marie-Paule Jammal; Tom Pickles; Patrick O Richard; Fred Saad
Journal:  Can Urol Assoc J       Date:  2017-12-19       Impact factor: 1.862

4.  Defining a new testosterone threshold for medical castration: Results from a prospective cohort series.

Authors:  Shawn Dason; Christopher B Allard; Justin Tong; Bobby Shayegan
Journal:  Can Urol Assoc J       Date:  2013 May-Jun       Impact factor: 1.862

5.  LHRH Agonists for the Treatment of Prostate Cancer: 2012.

Authors:  Herbert Lepor; Neal D Shore
Journal:  Rev Urol       Date:  2012

6.  Investigation of female survival benefit in metastatic melanoma.

Authors:  B Richardson; A Price; M Wagner; V Williams; P Lorigan; S Browne; J G Miller; S Mac Neil
Journal:  Br J Cancer       Date:  1999-08       Impact factor: 7.640

7.  Comparison of the Efficacy of Two Brands of Triptorelin (Microrelin and Diphereline) in Reducing Prostate-Specific Antigen and Serum Testosterone in Prostate Cancer: A Double-Blinded Randomized Clinical Trial.

Authors:  Farid Fazeli; Mohammad Reza Nowroozi; Mohsen Ayati; Sahar Latifi; Mohsen Taheri Mahmoodi; Abbas Norouzi Javidan; Hassan Jamshidian; Amir Arbab
Journal:  Nephrourol Mon       Date:  2015-05-25

8.  Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide.

Authors:  Myungsun Shim; Woo Jin Bang; Cheol Young Oh; Yong Seong Lee; Jin Seon Cho
Journal:  Investig Clin Urol       Date:  2019-05-21

Review 9.  Definition of Castrate Resistant Prostate Cancer: New Insights.

Authors:  Juan Morote; Adriana Aguilar; Jacques Planas; Enrique Trilla
Journal:  Biomedicines       Date:  2022-03-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.